TOKYO – Rani Therapeutics LLC is working on a delivery system for insulin that could provide relief for millions of people who must undergo regular painful injections to deal with conditions such as diabetes, rheumatoid arthritis, osteoporosis and multiple sclerosis.
TOKYO – Despite a protest by a 110-strong group of shareholders that comprises the founding family and former executives of Takeda Pharmaceutical Co. Ltd., Japan's largest drug manufacturer, Christophe Weber has been approved as the company's first foreign president and chief executive officer.
TOKYO – Despite a protest by a 110-strong group of shareholders that comprises the founding family and former executives of Takeda Pharmaceutical Co. Ltd., Japan's largest drug manufacturer, Christophe Weber has been approved as the company's first foreign president and chief executive officer.
TOKYO – Japan's Ministry of Health, Labor and Welfare (MHLW) approved six new drugs, including one biosimilar, underscoring the country's drive to speed up drug approvals. And, in some instances, the approvals were done faster than in the U.S.
TOKYO – Japan's Ministry of Health, Labor and Welfare (MHLW) approved six new drugs, including one biosimilar, underscoring the country's drive to speed up drug approvals. And, in some instances, the approvals were done faster than in the U.S.
TOKYO – Japan's Taiho Oncology Inc. reported positive results from a global phase III trial of its oral combination anticancer drug TAS-102 (trifluridine and tipiracil hydrochloride) in refractory metastatic colorectal cancer (mCRC).
TOKYO – Japan's Taiho Oncology Inc. reported positive results from a global phase III trial of its oral combination anticancer drug TAS-102 (trifluridine and tipiracil hydrochloride) in refractory metastatic colorectal cancer (mCRC).
TOKYO – Representatives of various U.S. organizations are urging Japan to reconsider a proposal that would revise reimbursement prices for pharmaceuticals on an annual, rather than a biennial, basis.
TOKYO – Representatives of various U.S. organizations are urging Japan to reconsider a proposal that would revise reimbursement prices for pharmaceuticals on an annual, rather than a biennial, basis.
